EUR-Lex Access to European Union law
This document is an excerpt from the EUR-Lex website
Document 22023D0032
Decision of the EEA Joint Committee No 227/2019 of 27 September 2019 amending Annex II (Technical regulations, standards, testing and certification) to the EEA Agreement [2023/32]
Decision of the EEA Joint Committee No 227/2019 of 27 September 2019 amending Annex II (Technical regulations, standards, testing and certification) to the EEA Agreement [2023/32]
Decision of the EEA Joint Committee No 227/2019 of 27 September 2019 amending Annex II (Technical regulations, standards, testing and certification) to the EEA Agreement [2023/32]
OJ L 4, 5.1.2023, p. 42–43
(BG, ES, CS, DA, DE, ET, EL, EN, FR, GA, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
Date of entry into force unknown (pending notification) or not yet in force.
|
5.1.2023 |
EN |
Official Journal of the European Union |
L 4/42 |
DECISION OF THE EEA JOINT COMMITTEE No 227/2019
of 27 September 2019
amending Annex II (Technical regulations, standards, testing and certification) to the EEA Agreement [2023/32]
THE EEA JOINT COMMITTEE,
Having regard to the Agreement on the European Economic Area (“the EEA Agreement”), and in particular Article 98 thereof,
Whereas:
|
(1) |
Commission Implementing Regulation (EU) 2019/637 of 23 April 2019 approving cholecalciferol as an active substance for use in biocidal products of product-type 14 (1) is to be incorporated into the EEA Agreement. |
|
(2) |
Commission Implementing Decision (EU) 2019/641 of 17 April 2019 on the terms and conditions of the authorisation of a biocidal product family containing 1R-trans phenothrin referred by Ireland in accordance with Article 36 of Regulation (EU) No 528/2012 of the European Parliament and of the Council (2) is to be incorporated into the EEA Agreement. |
|
(3) |
Annex II to the EEA Agreement should therefore be amended accordingly, |
HAS ADOPTED THIS DECISION:
Article 1
The following points are inserted after point 12zzzzzw (Commission Implementing Decision (EU) 2018/1251) of Chapter XV of Annex II to the EEA Agreement:
|
‘12zzzzzx. |
32019 R 0637: Commission Implementing Regulation (EU) 2019/637 of 23 April 2019 approving cholecalciferol as an active substance for use in biocidal products of product-type 14 (OJ L 109, 24.4.2019, p. 13). |
|
12zzzzzy. |
32019 D 0641: Commission Implementing Decision (EU) 2019/641 of 17 April 2019 on the terms and conditions of the authorisation of a biocidal product family containing 1R-trans phenothrin referred by Ireland in accordance with Article 36 of Regulation (EU) No 528/2012 of the European Parliament and of the Council (OJ L 109, 24.4.2019, p. 26).’ |
Article 2
The texts of Implementing Regulation (EU) 2019/637 and Implementing Decision (EU) 2019/641 in the Icelandic and Norwegian languages, to be published in the EEA Supplement to the Official Journal of the European Union, shall be authentic.
Article 3
This Decision shall enter into force on 28 September 2019, provided that all the notifications under Article 103(1) of the EEA Agreement have been made (*1).
Article 4
This Decision shall be published in the EEA Section of, and in the EEA Supplement to, the Official Journal of the European Union.
Done at Brussels, 27 September 2019.
For the EEA Joint Committee
The President
Gunnar PÁLSSON
(1) OJ L 109, 24.4.2019, p. 13.
(2) OJ L 109, 24.4.2019, p. 26.
(*1) No constitutional requirements indicated.